Related Experiment Video
Updated: Jan 18, 2026

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
Published on: June 4, 2020
Combined role of thromboelastography and coagulation indicators in predicting thromboembolism risk in cancer patients
Liqiu Huang1, Wei Dong2, Xiaojie Hu3
1Department of Laboratory, Tangshan Central Hospital, Tangshan, Hebei, China.
Objective:
Exploring the application value of thromboelastography (TEG) and four coagulation indicators in the risk assessment of thromboembolism (TE) in cancer patients.
Methods:
Retrospectively analyzed the clinical data of 160 cancer patients. Among them, 45 patients experienced thromboembolism (TE group) and 115 patients did not experience thromboembolism (non-TE group). We analyzed the levels of TEG and coagulation indicators in the two groups of patients and the risk factors for TE in cancer patients.
Results:
The Angle and MA of the thromboembolic group were significantly higher than those of the non-TE group, whereas K and R were significantly lower than those of the non-TE group (P < 0.05). D-dimer (D-D) and fibrinogen (FIB) levels in the thromboembolic group were significantly higher than those in the non-TE group, while activated partial thromboplastin time (APTT), prothrombin time (PT), and platelet count (PLT) were significantly lower than those in the non-TE group (P < 0.05). Binary logistic regression analysis confirmed that angle, maximum amplitude (MA), K, R, D-D, APTT, PT, and PLT were all important influencing factors for the occurrence of TE in cancer patients (P < 0.05).
Conclusions:
TEG and coagulation index level detection have high application values in the risk assessment of TE in cancer patients.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

